Otsuka America Pharmaceutical and Avanir Pharmaceuticals are working with southern New Jersey educational administrators to create specialists who can help Alzheimer’s patients and their families navigate the care continuum. The goal is to start a one-year training program at Camden County College that leads to a specialist’s certification. Those receiving…
The Jackson Laboratory (JAX) is receiving a $2.7 million U.S. government grant for a five-year research project on the mechanisms that underlie healthy aging and Alzheimer’s disease. Dr. Catherine Kaczorowski, an assistant professor at the Bal Harbor, Maine-based research organization, will direct the work. The grant is coming from the National Institute on…
Actors on CBS’s hit television series “Criminal Minds” have made a commercial to promote an Alzheimer’s Association awareness event called the Longest Day on June 21. The public service announcement builds on the show’s use of a character with Alzheimer’s to educate people about the disease. The commercial invites the…
The Dementia Discovery Fund will pump $5 million in initial financing into Cerevance, a start-up developing new approaches to treating dementia patients, 60 percent of whom have Alzheimer’s disease. The venture capital fund invests in companies and projects pursuing disease-modifying therapies for dementia. Cerevance has dual headquarters in Boston…
Neurotrope‘s investigational drug bryostatin might improve cognition and the ability of patients with moderate to severe Alzheimer’s disease to care for themselves, according to a Phase 2 trial. The placebo-controlled trial (NCT02431468) evaluated the safety, tolerability, and effectiveness of bryostatin in 147 people with Alzheimer’s…
Canada’s ProMIS Neurosciences today presented the latest results of its Alzheimer’s disease therapeutic program and discussed its lead candidate drug PMN 310 on the final day of the April 22-28 annual meeting of the American Academy of Neurology in Boston. The company’s chief development officer, Johanne Kaplan, presented the poster, “Achieving the optimal profile…
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) seeks help from leading experts, pharmaceutical companies and nonprofit organizations around the world to fight Alzheimer’s disease. Alzheimer’s disease is the most common cause of dementia among older adults, according to the Centers for Disease Control and Prevention (CDC). It is the fifth leading…
The high concentration of vitamin B12 in Marmite — a distinctly British food spread that many say is an acquired taste — was found to increase levels of gamma–aminobutyric acid (GABA) chemicals in the brain, which may protect against neurological disorders like Alzheimer’s disease, epilepsy or depression. This is according…
British pharmaceutical company Neuro-Bio has received $3.2 million in financing from Los Angeles-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s disease. This tool stems from a novel approach to Alzheimer’s pioneered in 2013 by Neuro-Bio’s founder and CEO, Susan Greenfield, and her team at Oxford University. Resulting…
The University of Wisconsin-Madison’s Alzheimer’s Disease Research Center and Cerveau Technologies are partnering in research on the stages of Alzheimer’s and other neurodegenerative diseases. Wisconsin established the center in 2009 to focus on preclinical Alzheimer’s. Cerveau is a partnership between Enigma Biomedical Group and Sinotau Pharmaceutical Group. It was created to…
Get regular updates to your inbox.